AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04218084
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo.
Trial: NCT02805582
Drug: 10ml ropivacain 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound guided nerve block
Trial: NCT00536809
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: given BID days 1-14
Trial: NCT03249181
Drug: Standard of Care (EFV + 2 NRTI backbone)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to receive standard of care will receive the currently used antiretroviral regimens in keeping with national policy.
Trial: NCT03646240
Drug: ABI-009
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For dose finding, ABI-009 will start at 5 mg/m2/dose IV, once a week for three weeks, in cohorts of 3 participants each using the standard 3+3 dose-finding design
Trial: NCT04382755
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard of care treatment + 1 week of prophylactic antibiotics (or until hospital discharge, whichever comes first)
Trial: NCT00799175
Drug: ropivacaine, ketorolac and epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Group A, 400 mg ropivicaine, 30 mg ketorolac and 0.5 mg epinephrine (total volume 166 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation in the following way: Before inserting the components, 20-30 ml are injected into the posterior capsule and before closure of the wound the rest is injected into the capsule incision, the synovium, the ligament and the subcutaneous tissue. After 21 postoperative hours in Group A, 200 mg ropivicaine, 30 mg ketorolac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
Trial: NCT00657904
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT00396032
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the initial treatment, 2 mL of placebo instilled into each lumen of the HD catheter; subsequent treatments were 2 mL of open-label tenecteplase
Trial: NCT02836743
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03396926
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally (PO)
Trial: NCT03603509
Drug: Fluad Vaccine
RxNorm normalized name: Fluad 2024-2025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLUAD is an inactivated influenza vaccine indicated for active immunization against influenza. disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUAD is. approved for use in persons 65 years of age and older.
Trial: NCT04612309
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient treated with at least 1 immunotherapy administration
Trial: NCT02675426
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet; Oral
Trial: NCT00637052
Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
Trial: NCT01001715
Drug: Placebo (for REGN475/SAR164877)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes
Trial: NCT03582007
Drug: One anti-pseudomonal antibiotic
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Either meropenem or piperacillin-tazobactam
Trial: NCT04622488
Drug: Diclofenac Potassium
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: - In the form of Insitu gel system can be applied as solution or suspension that undergoes gelation after administration. Applied once inside the root canal after chemo-mechanical preparation.
Trial: NCT01752712
Drug: CBSST + Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo spray will be administered intranasally (10 puffs of the spray, 5 in each nostril at each administration). CBSST groups will occur for an hour twice/week. Nasal spray will be administered an hour prior to the CBSST group.
Trial: NCT04958512
Drug: Yangxue Qingnao pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment group (20 cases) was treated with Yangxue Qingnao pill (2.5g / time, 3 times / day, orally for 6 months
Trial: NCT02969733
Drug: isotonic saline serum intravenous administration
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01566669
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before incision, patients in Group C (n = 120) receive 2 mL of normal saline IV. Thereafter, they receive 2 mL of normal saline IV every 12 h for 48 h. 30 min before the end of surgery, a mixture of 6 mL of ropivacaine 0.25% and 2mg morphine was given epidurally. Epidural patient-controlled analgesia was initiated by using ropivacaine 0.125% (1.25 mg/ml) and morphine 0.005% (0.05 mg/ml) with a basal infusion rate of 2 ml/h, a demand dose of 2 ml, and a 15-min lockout.
Trial: NCT03110315
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic suvorexant 10 mg tablet.
Trial: NCT03365609
Drug: concomitant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole+Amoxicillin+Clarithromycin+Metronidazole
Trial: NCT01396278
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching fluticasone propionate HFA MDI
Trial: NCT04470622
Drug: Saline Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline Placebo, once daily (QD) for 14 days.
Trial: NCT03519022
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The pharmacodynamic effects of placebo will be determined during maintenance on placebo and duloxetine.
Trial: NCT03171610
Drug: Sufentanil group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA device containing sufentanil (3 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml was connected.
Trial: NCT03171610
Drug: Fentanyl group
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PCA device containing fentanyl (20 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml was connected.
Trial: NCT01461655
Drug: marketed topical NSAID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily application, 4 weeks
Trial: NCT01461655
Drug: vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily application, 4 weeks
Trial: NCT01461655
Drug: marketed topical retinoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily application, 4 weeks
Trial: NCT03675815
Drug: TDF 300 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg orally once daily for 96 weeks
Trial: NCT03675815
Drug: 3TC 300 MG Oral Tablet
RxNorm normalized name: 3TC 300 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg orally once daily for 96 weeks. Choice of 3TC or FTC will be determined by clinician
Trial: NCT00786019
Drug: Ascorbic Acid (Vitamin C)
RxNorm normalized name: Ascorbic acid (vitamin C), plain
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During one exercise study visit, 0.06 grams of Vitamin C per kilogram fat-free mass per 100 milliliters (mL) of normal saline administered; Subjects will receive a bolus of 100mL Vitamin C solution given at 5ml/minute over 20 minutes followed by a drip-infusion given at 1.7ml/minute.
Trial: NCT03948737
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00268554
Drug: caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01142089
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two matching tablets) orally twice daily for 3 days (72 hours).
Trial: NCT00079144
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02387788
Drug: AKB-9778
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 2a open-label study to assess the efficacy and safety of subcutaneous 15mg AKB-9778 administered twice daily for 84 days in subjects with macular edema due to RVO.
Trial: NCT02775227
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04444427
Drug: GLR2007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally, once daily for 21 days followed by a 7-day treatment holiday.
Trial: NCT01994499
Drug: Medical drainage
RxNorm normalized name: PLEURX DRAINAGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical pleural drainage
Trial: NCT01757691
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01066442
Drug: BF2.649 (Pitolisant)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D
Trial: NCT03923478
Drug: ABI-M201
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Treatment
Trial: NCT03923478
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Treatment
Trial: NCT01241552
Drug: SOC
RxNorm normalized name: Isocet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (SOC) for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metranidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
Trial: NCT00727233
Drug: Toxicity, Pharmacokinetics
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00727233
Drug: Pharmacodynamics
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00727233
Drug: Radiographic Evaluation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03699319
Drug: 5-flurouracil
RxNorm normalized name: 1beta-D-2'-Deoxyribofuranosyl-5-flurouracil
DrugBank: Floxuridine (DB00322)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered at 400 mg/m2 as bolus followed by a 46-hr infusion at 2400 mg/m2, starting immediately after completion of folinic acid and irinotecan~Part of SOC mFOLFRINOX treatment combination of Oxaliplatin, Irniotecan, 5-flurouracil, and vitamin derivative (Folinic acid)
Trial: NCT03579875
Drug: Total Body Irradiation (TBI) (Plan 1)
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 cGy with thymic shielding on day -6
Trial: NCT03579875
Drug: Cyclophosphamide (CY) (Plan 1)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg/kg IV daily on days -5, -4, -3, and -2
Trial: NCT03579875
Drug: Cyclophosphamide (CY) (Plan 2)
RxNorm normalized name: cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 mg/kg IV daily on days -5, -4, -3, and -2
Trial: NCT00528866
Drug: LHRH agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHRH agonist (such as leuprolide, goserelin, buserelin, or triptorelin) for 6 months, starting within 6 weeks after registration
Trial: NCT01881217
Drug: BAY1179470
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY1179470 will be administered as a 1-hour intravenous infusion.
Trial: NCT00306137
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution was supplied in identical vials and will consist of 200mL of 0.9% sodium chloride.
Trial: NCT02923115
Drug: DS-1040b
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single, continuous intravenous infusion over 12 to 24 hours (depending on cohort)
Trial: NCT02923115
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single, continuous intravenous infusion of 0.9% sodium chloride over 12 to 24 hours
Trial: NCT02888665
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03455192
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04401020
Drug: SAR442257
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Sterile powder for reconstitution Route of administration: Intravenous infusion
Trial: NCT02701088
Drug: 5Fluorouracile and Mitomycin-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All the patients will receive radiochemotherapy with two cycles of 5FU (1,000 mg/m²/d with 96-h infusion, days 1-5 and 29-33 of SIB-IMRT) and Mitomycin-C (10 mg/m², days 1 and 29).
Trial: NCT00712660
Drug: antipsychotic dose increase
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% increase in the dose of current antipsychotic medication
Trial: NCT01221454
Drug: Conserved therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral or intravenous administration
Trial: NCT02153476
Drug: 2.0mg of ALG-1001
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00101894
Drug: FOLFOX-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The FOLFOX-4 regimen will be administered every 2 weeks as follows:~Day 1: oxaliplatin (ELOXATIN™) 85 mg/m2 IV infusion and leucovorin racemate 200 mg/m2 (or 100 mg/m2 l-LV) IV infusion given over 120 ± 10 minutes at the same time in separate bags using a Y-line, followed by 5-FU 400 mg/m2 IV bolus given over 2 to 4 minutes, followed by 5-FU 600 mg/m2 IV infusion as a 22-hour ± 2 hours continuous infusion Day 2: leucovorin racemate 200 mg/m2 (or 100 mg/m2 l-LV) IV infusion over 120 ± 10 minutes, followed by 5-FU 400 mg/m2 IV bolus given over 2 to 4 minutes, followed
Trial: NCT00101894
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan will be administered over 90 minutes ± 15 minutes on day 1 of each 2-week cycle. Leucovorin will be administered over 2 hours ± 15 minutes during the irinotecan infusion but without mixing, immediately followed by a 5-FU bolus and a 5-FU 46-hour ± 2-hour continuous intravenous infusion.
Trial: NCT02410031
Drug: Cyproterone acetate 2mg/ethinylestradiol 35 μg (Diane-35)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate 2mg/ethinylestradiol 35 μg
Trial: NCT00549120
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for propranolol tablets
Trial: NCT02556931
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days -6 and -5: 14.5 mg/kg IV daily Days 3 and 4: 50 mg/kg IV daily
Trial: NCT00022126
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00022126
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00022126
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00022126
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02532140
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00488839
Drug: IPX056 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPX056 Extended Release capsule containing 20 mg baclofen
Trial: NCT00488839
Drug: IPX056 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPX056 Extended Release capsule containing 10 mg baclofen
Trial: NCT00488839
Drug: IPX056 30 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPX056 Extended Release capsule containing 30 mg baclofen
Trial: NCT00488839
Drug: IPX056 35 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPX056 Extended Release capsule containing 35 mg baclofen
Trial: NCT00488839
Drug: Placebo IPX056 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule for IPX056 20 mg
Trial: NCT00488839
Drug: Placebo IPX056 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule for IPX056 40 mg
Trial: NCT00727896
Drug: Diabetes Treatment
RxNorm normalized name: Diabetes Ancillary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Life style modification and drug therapy
Trial: NCT04130854
Drug: APX005M, mFOLFOX, and Radiation Therapy 5Gy x 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. APX005M 0.3mg/kg intravenously on day 3 of radiation and on day 3 of cycles 1-5 of mFOLFOX~2. Short course radiation therapy 5 Gy x 5 days~3. Oxaliplatin 85mg/m2 intravenous day 1 of each cycle~4. Leucovorin 400mg/m2 IV Day 1 of each cycle~5. 5-FU 2400 mg/m2 continuous infusion over 46 hours of each cycle
Trial: NCT04130854
Drug: mFOLFOX and Radiation Therapy 5Gy x 5 days
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Short course radiation therapy 5 Gy x 5 days~2. Oxaliplatin 85mg/m2 intravenous day 1 of each cycle~3. Leucovorin 400mg/m2 IV Day 1 of each cycle~4. 5-FU 2400 mg/m2 continuous infusion over 46 hours of each cycle
Trial: NCT00324129
Drug: MGCD0103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MGCD0103 given orally three times per week.
Trial: NCT00874770
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral, 0 mg, Daily 48 weeks
Trial: NCT03875378
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo weekly patch
Trial: NCT03891667
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive disulfiram for 4 weeks followed by placebo for 4 weeks or disulfiram for 8 weeks.
Trial: NCT02138617
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200-400 mg/m2 IV over 2 hours, Day 1 and Day 15
Trial: NCT02515955
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive minocycline 100 mg as capsule twice daily.
Trial: NCT00002967
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002967
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00404456
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin 3 mg once-daily
Trial: NCT02169817
Drug: Oral Rehydration Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:vials/sachets for solution Route of administration: oral
Trial: NCT03496324
Drug: Nurofen for Children®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurofen for Children® 400 mg/10 ml
Trial: NCT04406883
Drug: Extraction + filled with Simvastatin solution impregnated gelatin sponge
RxNorm normalized name: succinylated gelatin Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All two first premolars were extracted carefully, have used periotome as a means of atraumatic extraction that facilitated the removal of teeth with minimum damage to the surrounding alveolar bone, teeth to be extracted should have minimum periapical changes radiographically; with decreasing soft tissue reflection; the socket was tan gently irrigated with normal saline and hemostasis was achieved. It must be noted that A group (Extraction + filled with Simvastatin (Poursina Pharmaceutical Co. Tehran-Iran) solution impregnated gelatin sponge (Maquira Industry Dental Products S.A. Brazil) and B group (Extraction + without Simvastatin solution impregnated gelatin sponge), was placed in one of the sockets.
Trial: NCT00092651
Drug: MK0653A, ezetimibe (+) simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01188005
Drug: Vitamin A, Vitamin C, Vitamin E, Allopurinol, N-Acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A 50,000 IU, Vitamin C 1000 mg , Vitamin E 200 mg, Allopurinol 600 mg, N-Acetylcysteine 2 g. Duration is set for 60 days
Trial: NCT03496324
Drug: Algifor® Junior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algifor® Junior 400 mg/20 ml
Trial: NCT03563144
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine
Trial: NCT03563144
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Trial: NCT03563144
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
Trial: NCT01365676
Drug: GAMALINE® + HIPERICIN®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAMALINE® 900mg + HIPERICIN 300mg T0 = 2 soft caps of each / day (1st month) T1-T6 = 1 soft caps of each / day (2nd - 6th month)